Ernexa Therapeutics Inc. Available-for-sale Securities, Gross Realized Losses
Ernexa Therapeutics Inc. (ERNA) reported Available-for-sale Securities, Gross Realized Losses of $30.00 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-30.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2012-03-30
- Ernexa Therapeutics Inc. available-for-sale securities, gross realized losses for the quarter ending 2011-12-31 was $0.00.
- Ernexa Therapeutics Inc. available-for-sale securities, gross realized losses for the quarter ending 2011-09-30 was $12.00K.
- Ernexa Therapeutics Inc. available-for-sale securities, gross realized losses for fiscal 2011 was $30.00K.
| Period end | Available-for-sale Securities, Gross Realized Losses 3 month | Available-for-sale Securities, Gross Realized Losses 6 month | Available-for-sale Securities, Gross Realized Losses 9 month | Available-for-sale Securities, Gross Realized Losses 12 month |
|---|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $12.00K derived: sum of 2 quarters · filed 2012-03-30 | $30.00K 10-K · filed 2012-03-30 | |
| 2011-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $30.00K 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $18.00K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |